Photo from Mohamad Mohty/X
Jun 20, 2024, 11:53
Mohamad Mohty shares long-term survival outcomes from the phase II MagnetisMM-3 study – Multiple Myeloma Hub
Multiple Myeloma Hub shared on X/Twitter:
“CONGRESS | POSTER | EHA2024 | Mohamad Mohty shares long-term survival outcomes from the phase II MagnetisMM-3 study of elranatamab in patients with RRMM, N=123. ORR remained at 61%, with median DoR not reached.”
Source: Multiple Myeloma Hub/X
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Feb 21, 2025, 09:35
Feb 21, 2025, 09:18
Feb 21, 2025, 09:07
Feb 21, 2025, 09:00
Feb 21, 2025, 08:19
Feb 21, 2025, 06:20